AbCellera Biologics Inc. – NASDAQ:ABCL
AbCellera Biologics stock price today
$4.3
+1.30
+43.81%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
AbCellera Biologics stock price monthly change
-4.17%
month
AbCellera Biologics stock price quarterly change
-4.17%
quarter
AbCellera Biologics stock price yearly change
-48.45%
year
AbCellera Biologics key metrics
Market Cap | 849.17M |
Enterprise value | 1.77B |
P/E | 15.17 |
EV/Sales | 3.65 |
EV/EBITDA | 6.51 |
Price/Sales | 4.27 |
Price/Book | 1.68 |
PEG ratio | 140.42 |
EPS | -0.50 |
Revenue | 35.78M |
EBITDA | -185.90M |
Income | -146.89M |
Revenue Q/Q | -18.35% |
Revenue Y/Y | -80.23% |
Profit margin | 32.66% |
Oper. margin | 46.78% |
Gross margin | 86.31% |
EBIT margin | 46.78% |
EBITDA margin | -519.46% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAbCellera Biologics stock price history
AbCellera Biologics stock forecast
AbCellera Biologics financial statements
Average Price Target
$5
Potential upside: 16.27%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 10.05M | -30.52M | -303.58% |
|---|---|---|---|
| Sep 2023 | 6.59M | -28.61M | -433.55% |
| Dec 2023 | 9.17M | -47.15M | -513.67% |
| Mar 2024 | 9.95M | -40.61M | -407.98% |
| Jun 2023 | 1537166000 | 342.33M | 22.27% |
|---|---|---|---|
| Sep 2023 | 1512190000 | 329.41M | 21.78% |
| Dec 2023 | 1488094000 | 335.77M | 22.56% |
| Mar 2024 | 1463096000 | 222.60M | 15.21% |
| Jun 2023 | 19.90M | -34.39M | 419K |
|---|---|---|---|
| Sep 2023 | -106K | -12.78M | 6.63M |
| Dec 2023 | -19.61M | -24.32M | 3.76M |
| Mar 2024 | -41.70M | 29.91M | 2.83M |
AbCellera Biologics alternative data
| Aug 2023 | 525 |
|---|---|
| Sep 2023 | 590 |
| Oct 2023 | 590 |
| Nov 2023 | 590 |
| Dec 2023 | 630 |
| Jan 2024 | 630 |
| Feb 2024 | 630 |
| Mar 2024 | 586 |
| Apr 2024 | 586 |
| May 2024 | 586 |
| Jun 2024 | 586 |
| Jul 2024 | 586 |
AbCellera Biologics other data
40.94%
+3.19%
of ABCL is owned by hedge funds
171
+17
116.54M
-1.03M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 40000 | 0 |
| Nov 2023 | 30000 | 0 |
| Aug 2024 | 283516 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | HANSEN CARL L. G. director, 10 perc.. | Share option (right to buy) | 56,125 | $2.7 | $151,538 | ||
Option | HANSEN CARL L. G. director, 10 perc.. | Common Shares | 56,125 | $2.7 | $151,538 | ||
Option | HANSEN CARL L. G. director, 10 perc.. | Share option (right to buy) | 56,125 | $2.7 | $151,538 | ||
Option | HANSEN CARL L. G. director, 10 perc.. | Common Shares | 56,125 | $2.7 | $151,538 | ||
Purchase | THERMOPYLAE HOLDINGS LTD. 10 percent owner | Common Shares | 283,516 | $2.61 | $739,977 | ||
Option | LECAULT VERONIQUE director, officer.. | Share option (right to buy) | 83,334 | $0.19 | $15,667 | ||
Option | LECAULT VERONIQUE director, officer.. | Common Shares | 83,334 | $0.19 | $15,667 | ||
Option | HANSEN CARL L. G. director, 10 perc.. | Share option (right to buy) | 56,125 | $2.7 | $151,538 | ||
Option | HANSEN CARL L. G. director, 10 perc.. | Common Shares | 56,125 | $2.7 | $151,538 | ||
Option | HANSEN CARL L. G. director, 10 perc.. | Share option (right to buy) | 56,125 | $2.7 | $151,538 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 20 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
OmniAb: Plenty Of Potential
AbCellera Biologics: TCE Program Alone Could Be Worth More Than The Current Market Cap
Confounded's Complete All-Weather Portfolio Revealed
OmniAb: Legitimate Competition To AbCellera In Antibody Discovery
AbCellera Biologics: My Updated Current Valuation Estimate
10 Potential 10x Return Stocks For The Next 10 Years
AbCellera Biologics: Q3 Commentary - Moving Up The Value Stack
Unusual Mid-Cap Insider Activity
AbCellera Biologics: COVID Antibody Set To Provide Continued Funding
-
What's the price of AbCellera Biologics stock today?
One share of AbCellera Biologics stock can currently be purchased for approximately $4.3.
-
When is AbCellera Biologics's next earnings date?
Unfortunately, AbCellera Biologics's (ABCL) next earnings date is currently unknown.
-
Does AbCellera Biologics pay dividends?
No, AbCellera Biologics does not pay dividends.
-
How much money does AbCellera Biologics make?
AbCellera Biologics has a market capitalization of 849.17M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 92.17% to 38.03M US dollars.
-
What is AbCellera Biologics's stock symbol?
AbCellera Biologics Inc. is traded on the NASDAQ under the ticker symbol "ABCL".
-
What is AbCellera Biologics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of AbCellera Biologics?
Shares of AbCellera Biologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are AbCellera Biologics's key executives?
AbCellera Biologics's management team includes the following people:
- Mr. Tryn T. Stimart Esq., J.D. Chief Legal Officer, Chief Compliance Officer & Corporation Sec.(age: 55, pay: $635,630)
- Dr. Carl L.G. Hansen Ph.D. Chief Executive Officer, Pres & Chairperson(age: 51, pay: $424,680)
- Dr. Veronique Lecault Ph.D. Chief Operating Officer & Director(age: 40, pay: $267,540)
-
How many employees does AbCellera Biologics have?
As Jul 2024, AbCellera Biologics employs 586 workers.
-
When AbCellera Biologics went public?
AbCellera Biologics Inc. is publicly traded company for more then 4 years since IPO on 11 Dec 2020.
-
What is AbCellera Biologics's official website?
The official website for AbCellera Biologics is abcellera.com.
-
Where are AbCellera Biologics's headquarters?
AbCellera Biologics is headquartered at 2215 Yukon Street, Vancouver, BC.
-
How can i contact AbCellera Biologics?
AbCellera Biologics's mailing address is 2215 Yukon Street, Vancouver, BC and company can be reached via phone at +60 4 559 9005.
-
What is AbCellera Biologics stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for AbCellera Biologics in the last 12 months, the avarage price target is $5. The average price target represents a 16.27% change from the last price of $4.3.
AbCellera Biologics company profile:
AbCellera Biologics Inc.
abcellera.comExchange:
NASDAQ
Full time employees:
586
Industry:
Biotechnology
Sector:
Healthcare
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
2215 Yukon Street
Vancouver, BC V5Y 0A1
Vancouver, BC V5Y 0A1
CIK: 0001703057
ISIN: CA00288U1066
CUSIP: 00288U106
